AIM logo

AIM IMMUNOTECH INC

AIMNYSE AMERICAN
🏆 #4947 by market capUS Equity
$0.17▼ $0.00 (−0.06%)
Market closed · at close
🔔
Track AIM
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 0.1%
7d▲ 1.3%
14d▼ 4.5%
30d▼ 3.7%
ytd▼ 85.1%
1y▼ 93.1%
🏦Market Cap
$7M
Small Cap
📈Revenue Growth (YoY)
-21.5%
Declining
📊Gross Margin
-23.2%
Thin
💵FCF Margin
—
⚖️P/S Ratio
70.6x
Expensive
Otter Score
—
Insufficient data

Trading Snapshot

Day Range
$0.17 – $0.17
52-Week Range
$0.15 – $2.79
Volume (shares)
708
Avg Volume (shares)
—
Shares Outstanding
39.9M
Next Earnings
—

Fundamentals Snapshot

Annual Revenue
—
Last Q Revenue
—
P/E Ratio
—
P/S Ratio
70.6x
EPS (TTM)
$-3.93
Dividend Yield
—
Dilution (1yr)
+96.1%
AIM logo

AIM IMMUNOTECH INC

AIM
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$88K▼ −48.2% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
-284.1%▼ −447.4% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$11M▼ −46.8% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$11M▼ −24.0% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
3.1M▲ +96.1% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
−$4M▼ −$3M YoY
StockOtter · stockotter.space

About AIM IMMUNOTECH INC

AIM ImmunoTech Inc., an immuno-pharmaceutical company based in Ocala, Florida, focuses on discovering and advancing treatments for a diverse array of cancers, viral infections, and immune system disorders across the United States. Its primary drug offerings include Ampligen (rintatolimod), a large macromolecular double-stranded ribonucleic acid compound developed for chronic fatigue syndrome, and Alferon N Injection (Interferon alfa), a purified, naturally derived, multi-species alpha interferon prescribed for genital warts. Furthermore, Ampligen is currently undergoing investigation for its potential application in treating pancreatic, renal cell, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company, originally incorporated in 1966, was formerly known as Hemispherx Biopharma, Inc. until its name change in August 2019.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100
Analyst data unavailable.

Latest News & Updates

News unavailable.